Ketogenic Diet as a Novel Treatment for Glioblastoma
Scientists are trying to develop combination therapies for the treatment of malignant diseases, such as glioblastoma, that will increase the survival rate and reduce the side effects. Studies have shown that the efficacy of the classic treatment for glioblastoma, surgical resection combined with chemotherapy and radiation, will be greater if the metabolism of cancer cells is modified by nutritional habits. A ketogenic diet with caloric restriction is a key strategy in killing tumor cells by decreasing the amount of glucose as a source of energy, suppressing oxidative stress in tumor cells, inhibiting the signaling pathways of tumor markers, and reducing tumor angiogenesis and growth factors. Moreover, the application of a ketogenic diet and caloric restriction reduces the side effects of the chemotherapy and radiation used in the treatment of cancer cells. Another advantage of a ketogenic diet in the treatment of glioblastoma is the accessibility and affordability of changing nutritional habits for all socioeconomic classes. In vitro and in vivo studies have shown the efficacy of a ketogenic diet, but more clinical studies are needed. Animal studies have demonstrated that a ketogenic diet increased the performance and survival of mouse models with malignant glioma. There are currently some pilot studies underway in the United States and Germany that will be completed by 2018.
1.Anton K, Baehring JM, Mayer T. Glioblastoma multiforme: overview of current treatment and future perspectives. Hematol Oncol Clin North Am 2012;26:825–53. [CrossRef]
2. Weller M, Stupp R, Hegi M, Wick W. Individualized targeted therapy for glioblastoma: fact or fiction? Cancer J 2012;18:40– 4. [CrossRef]
3. Brennan C. Genomic profiles of glioma. Curr Neurol Neurosci Rep 2011;11:291–7. [CrossRef]
4. Venur VA, Peereboom DM, Ahluwalia MS. Current medical treatment of glioblastoma. Cancer Treat Res 2015;163:103–15.
5. Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N. Antiangiogenic therapy for high-grade glioma. Cochrane Database Syst Rev 2014:CD008218. [CrossRef]
6. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014;370:699– 708. [CrossRef]
7. Prust MJ, Jafari-Khouzani K, Kalpathy-Cramer J, Polaskova P, Batchelor TT, Gerstner ER, et al. Standard chemoradiation for glioblastoma results in progressive brain volume loss. Neurology 2015;85:683–91. [CrossRef]
8. Crespo I, Vital AL, Gonzalez-Tablas M, Patino Mdel C, Otero A, Lopes MC, et al. Molecular and Genomic Alterations in Glioblastoma Multiforme. Am J Pathol 2015;185:1820–33. [CrossRef]
9. Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, et al. Toward precision medicine in glioblastoma: the promise and the challenges. Neuro Oncol 2015;17:1051–63.
10. Rosenberg S, Verreault M, Schmitt C, Guegan J, Guehennec J, Levasseur C, et al. Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors. Neuro Oncol 2017;19:219–28.
11. Schwartzbaum J, Edlinger M, Zigmont V, Stattin P, Rempala GA, Nagel G, et al. Associations between prediagnostic blood glucose levels, diabetes, and glioma. Sci Rep 2017;7:1436.
12. Warburg O, Wind F, Negelein E. The Metabolism of Tumors in the Body. J Gen Physiol 1927;8:519–30. [CrossRef]
13. Seyfried TN, Kiebish MA, Marsh J, Shelton LM, Huysentruyt LC, Mukherjee P. Metabolic management of brain cancer. Biochim Biophys Acta 2011;1807:577–94. [CrossRef]
14. Marie SK, Shinjo SM. Metabolism and brain cancer. Clinics (Sao Paulo) 2011;66 Suppl 1:33–43. [CrossRef]
15. Puzio-Kuter AM. The Role of p53 in Metabolic Regulation. Genes Cancer 2011;2:385–91. [CrossRef]
16. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006;126:107–20. [CrossRef]
17. Semenza GL. Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol 2009;19:12–6. [CrossRef]
18. Yeung SJ, Pan J, Lee MH. Roles of p53, MYC and HIF-1 in regulating glycolysis - the seventh hallmark of cancer. Cell Mol Life Sci 2008;65:3981–99. [CrossRef]
19. Winter SF, Loebel F, Dietrich J. Role of ketogenic metabolic therapy in malignant glioma: A systematic review. Crit Rev Oncol Hematol 2017;112:41–58. [CrossRef]
20. Cross JH. New research with diets and epilepsy. J Child Neurol 2013;28:970–4. [CrossRef]
21. Vohra M, Lemieux GA, Lin L, Ashrafi K. The beneficial effects of dietary restriction on learning are distinct from its effects on longevity and mediated by depletion of a neuroinhibitory metabolite. PLoS Biol 2017;15:e2002032. [CrossRef]
22. Daugherty D, Goldberg J, Fischer W, Dargusch R, Maher P, Schubert D. A novel Alzheimer's disease drug candidate targeting inflammation and fatty acid metabolism. Alzheimers Res Ther 2017;9:50. [CrossRef]
23. Stafstrom CE, Rho JM. The ketogenic diet as a treatment paradigm for diverse neurological disorders. Front Pharmacol 2012;3:59. [CrossRef]
24. Scheck AC, Abdelwahab MG, Fenton KE, Stafford P. The ketogenic diet for the treatment of glioma: insights from genetic profiling. Epilepsy Res 2012;100:327–37. [CrossRef]
25. Weinberg F, Chandel NS. Reactive oxygen species-dependent signaling regulates cancer. Cell Mol Life Sci 2009;66:3663–73.
26. Karihtala P, Soini Y. Reactive oxygen species and antioxidant mechanisms in human tissues and their relation to malignancies. APMIS 2007;115:81–103. [CrossRef]
27. Mukherjee P, Abate LE, Seyfried TN. Antiangiogenic and proapoptotic effects of dietary restriction on experimental mouse and human brain tumors. Clin Cancer Res 2004;10:5622–9. [CrossRef]
28. Jiang YS, Wang FR. Caloric restriction reduces edema and prolongs survival in a mouse glioma model. J Neurooncol 2013;114:25–32. [CrossRef]
29. D'Alessandris QG, Montano N, Cenci T, Martini M, Lauretti L, Bianchi F, et al. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience. Acta Neurochir (Wien) 2013;155:33–40. [CrossRef]
30. Rutz HP, Herr I. Glucocorticoid administration in antiemetic therapy: Is it safe? Cancer 2005;103:2656. [CrossRef]
31. Schwartz K, Chang HT, Nikolai M, Pernicone J, Rhee S, Olson K, et al. Treatment of glioma patients with ketogenic diets: report of two cases treated with an IRB-approved energy-restricted ketogenic diet protocol and review of the literature. Cancer Metab 2015;3:3. [CrossRef]
32. Scheck AC, Abdelwahab MG, Stafford P, Kim DY, Iwai S, Preul MC, et al. Mechanistic studies of the ketogenic diet as an adjuvant therapy for malignant gliomas. Cancer Res 2011;70:638. [CrossRef]
33. Zahra A, Fath MA, Opat E, Mapuskar KA, Bhatia SK, Ma DC, et al. Consuming a Ketogenic Diet while Receiving Radiation and Chemotherapy for Locally Advanced Lung Cancer and Pancreatic Cancer: The University of Iowa Experience of Two Phase 1 Clinical Trials. Radiat Res 2017;187:743–54. [CrossRef]
34. Morscher RJ, Aminzadeh-Gohari S, Feichtinger RG, Mayr JA, Lang R, Neureiter D, et al. Inhibition of Neuroblastoma Tumor Growth by Ketogenic Diet and/or Calorie Restriction in a CD1- Nu Mouse Model. PLoS One 2015;10:e0129802. [CrossRef]
35. Champ CE, Baserga R, Mishra MV, Jin L, Sotgia F, Lisanti MP, et al. Nutrient restriction and radiation therapy for cancer treatment: when less is more. Oncologist 2013;18:97–103. [CrossRef]
36. Simone BA, Dan T, Palagani A, Jin L, Han SY, Wright C, et al. Caloric restriction coupled with radiation decreases metastatic burden in triple negative breast cancer. Cell Cycle 2016;15:2265–74. [CrossRef]
37. Heydari AR, Unnikrishnan A, Lucente LV, Richardson A. Caloric restriction and genomic stability. Nucleic Acids Res 2007;35:7485–96. [CrossRef]
38. Klement RJ, Champ CE. Calories, carbohydrates, and cancer therapy with radiation: exploiting the five R's through dietary manipulation. Cancer Metastasis Rev 2014;33:217–29. [CrossRef]
39. Lussier DM, Woolf EC, Johnson JL, Brooks KS, Blattman JN, Scheck AC. Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet. BMC Cancer 2016;16:310. [CrossRef]
40. Scheck AC, Abdelwahab MG, Fenton KE, Stafford P. The ketogenic diet for the treatment of glioma: insights from genetic profiling. Epilepsy Res 2012;100:327–37. [CrossRef]
41. Hashim SA, VanItallie TB. Ketone body therapy: from the ketogenic diet to the oral administration of ketone ester. J Lipid Res 2014;55:1818–26. [CrossRef]
42. Pawlosky RJ, Kemper MF, Kashiwaya Y, King MT, Mattson MP,Veech RL. Effects of a dietary ketone ester on hippocampal glycolytic and tricarboxylic acid cycle intermediates and amino acids in a 3xTgAD mouse model of Alzheimer's disease. J Neurochem 2017;141:195–207. [CrossRef]
43. Kong G, Huang Z, Ji W, Wang X, Liu J, Wu X, et al. The Ketone Metabolite β-Hydroxybutyrate Attenuates Oxidative Stress in Spinal Cord Injury by Suppression of Class I Histone Deacetylases. J Neurotrauma 2017;34:2645–55. [CrossRef]
44. Zuccoli G, Marcello N, Pisanello A, Servadei F, Vaccaro S, Mukherjee P, et al. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: Case Report. Nutr Metab (Lond) 2010;7:33.
45. Schmidt M, Pfetzer N, Schwab M, Strauss I, Kämmerer U. Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: A pilot trial. Nutr Metab (Lond) 2011;8:54.